Patents by Inventor Dirk Gottschling
Dirk Gottschling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091729Abstract: A fluidizing device for treating particulate material and to a method using the fluidizing device. The fluidizing device includes an inflow base that can be moved relative to the fluidizing unit. The inflow base in an emptying position is positioned at least partly below the top edge of a material outlet by moving the inflow base relative to the fluidizing unit, so that a fluid connection is formed between the material outlet arranged in the distributor chamber and the fluidizing chamber past the inflow base in order to discharge treated material from the fluidizing unit.Type: ApplicationFiled: December 16, 2021Publication date: March 21, 2024Inventors: Dirk Zimmermann, Jochen Thies, Heinz Gottschling
-
Patent number: 11370771Abstract: The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R4, R7 to R10, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: February 14, 2019Date of Patent: June 28, 2022Assignee: Boehringer Ingelheim International GmbHInventors: Angela Kay Berry, Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Matthew Russell Netherton
-
Publication number: 20220152023Abstract: The present invention relates to compounds of formula (I) wherein A, X, R1, R2, R3, R4 and R5 are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, such as hypertension, preeclampsia, restenosis, a cardiac or respiratory condition, renal disease, liver disease, muscular dystrophy, fibrotic disorders, pain, ischemia or ischemic reperfusion injury, and cancer.Type: ApplicationFiled: April 7, 2020Publication date: May 19, 2022Inventors: Dirk GOTTSCHLING, Thierry BOUYSSOU, Niklas HEINE
-
Publication number: 20210163449Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: December 8, 2020Publication date: June 3, 2021Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Publication number: 20210053935Abstract: The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R4, R7 to R10, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: February 14, 2019Publication date: February 25, 2021Inventors: Angela Kay BERRY, Thierry BOUYSSOU, Dirk GOTTSCHLING, Niklas HEINE, Matthew Russell NETHERTON
-
Patent number: 10889568Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: October 25, 2018Date of Patent: January 12, 2021Assignee: Boehringer Ingelheim International GmbHInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Patent number: 10800757Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: October 25, 2018Date of Patent: October 13, 2020Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Publication number: 20190169167Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: October 25, 2018Publication date: June 6, 2019Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Publication number: 20190169168Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: October 25, 2018Publication date: June 6, 2019Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
-
Patent number: 10307402Abstract: The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.Type: GrantFiled: January 13, 2016Date of Patent: June 4, 2019Assignee: Boehringer Ingelheim International GmbHInventors: Dirk Gottschling, Joerg P. Hehn, Christoph Hoenke, Elke Langkopf
-
Patent number: 10093660Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.Type: GrantFiled: November 28, 2014Date of Patent: October 9, 2018Assignee: EVOTEC INTERNATONAL GMBHInventors: Joerg Kley, Andreas Blum, Dirk Gottschling, Joerg P. Hehn, Dieter Wiedenmayer
-
Publication number: 20180028500Abstract: The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.Type: ApplicationFiled: January 13, 2016Publication date: February 1, 2018Inventors: Dirk GOTTSCHLING, Joerg P. HEHN, Christoph HOENKE, Elke LANGKOPF
-
Patent number: 9708274Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.Type: GrantFiled: July 17, 2015Date of Patent: July 18, 2017Assignee: EVOTEC INTERNATIONAL GMBHInventors: Andreas Blum, Dirk Gottschling, Armin Heckel, Joerg P. Hehn, Bernhard Schmid, Dieter Wiedenmayer
-
Publication number: 20170174668Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.Type: ApplicationFiled: November 28, 2014Publication date: June 22, 2017Inventors: Joerg Kley, Andreas Blum, Dirk Gottschling, Joerg P. Hehn, Dieter Wiedenmayer
-
Publication number: 20150361055Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.Type: ApplicationFiled: July 17, 2015Publication date: December 17, 2015Inventors: Andreas BLUM, Dirk GOTTSCHLING, Armin HECKEL, Joerg P. HEHN, Bernhard SCHMID, Dieter WIEDENMAYER
-
Patent number: 9139577Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.Type: GrantFiled: June 26, 2014Date of Patent: September 22, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Andreas Blum, Dirk Gottschling, Armin Heckel, Joerg P. Hehn, Bernhard Schmid, Dieter Wiedenmayer
-
Patent number: 9029360Abstract: This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.Type: GrantFiled: March 27, 2013Date of Patent: May 12, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Dirk Gottschling, Heiner Ebel, Doris Riether, Bernd Wellenzohn
-
Patent number: 8952014Abstract: The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.Type: GrantFiled: December 17, 2009Date of Patent: February 10, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Dirk Gottschling, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Schaenzle, Dirk Stenkamp
-
Publication number: 20150005278Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.Type: ApplicationFiled: June 26, 2014Publication date: January 1, 2015Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Andreas BLUM, Dirk GOTTSCHLING, Armin HECKEL, Joerg P. HEHN, Bernhard SCHMID, Dieter WIEDENMAYER
-
Patent number: RE49699Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu